Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances

Overview

Journal J Cell Immunol

Date 2023 Mar 27

PMID 36968176

Authors

Yilun Deng

Ryan M Reyes

Chenghao Zhang

Jose Conejo-Garcia

Tyler J Curiel

Affiliations

Soon will be listed here.

Citing Articles

Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer.

Hillmann J, Maass N, Bauerschlag D, Florkemeier I BMC Med. 2025; 23(1):10.

PMID: 39762846 PMC: 11706140. DOI: 10.1186/s12916-024-03826-w.

References

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Malek T . The biology of interleukin-2. Annu Rev Immunol. 2007; 26:453-79. DOI: 10.1146/annurev.immunol.26.021607.090357. View

Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, Fuente D . Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol. 2013; 190(12):6230-8. DOI: 10.4049/jimmunol.1201895. View

Sun Z, Ren Z, Yang K, Liu Z, Cao S, Deng S . A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8 T-cell response and effective tumor control. Nat Commun. 2019; 10(1):3874. PMC: 6713724. DOI: 10.1038/s41467-019-11782-w. View

Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Humbelin M, van Gogh M . An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nat Commun. 2020; 11(1):6440. PMC: 7755894. DOI: 10.1038/s41467-020-20220-1. View

Arenas-Ramirez N, Woytschak J, Boyman O . Interleukin-2: Biology, Design and Application. Trends Immunol. 2015; 36(12):763-777. DOI: 10.1016/j.it.2015.10.003. View

Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J . Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017; 12(7):e0179431. PMC: 5497954. DOI: 10.1371/journal.pone.0179431. View

Overacre-Delgoffe A, Chikina M, Dadey R, Yano H, Brunazzi E, Shayan G . Interferon-γ Drives T Fragility to Promote Anti-tumor Immunity. Cell. 2017; 169(6):1130-1141.e11. PMC: 5509332. DOI: 10.1016/j.cell.2017.05.005. View

Verdeil G, Marquardt K, Surh C, Sherman L . Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A. 2008; 105(43):16683-8. PMC: 2575480. DOI: 10.1073/pnas.0805054105. View

10.

Klein C, Waldhauer I, Nicolini V, Freimoser-Grundschober A, Nayak T, Vugts D . Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017; 6(3):e1277306. PMC: 5384349. DOI: 10.1080/2162402X.2016.1277306. View

11.

Charych D, Hoch U, Langowski J, Lee S, Addepalli M, Kirk P . NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res. 2016; 22(3):680-90. DOI: 10.1158/1078-0432.CCR-15-1631. View

12.

Overacre-Delgoffe A, Vignali D . Treg Fragility: A Prerequisite for Effective Antitumor Immunity?. Cancer Immunol Res. 2018; 6(8):882-887. PMC: 6080214. DOI: 10.1158/2326-6066.CIR-18-0066. View

13.

Drerup J, Deng Y, Pandeswara S, Padron A, Reyes R, Zhang X . CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020; 80(22):5063-5075. PMC: 7669742. DOI: 10.1158/0008-5472.CAN-20-0002. View

14.

Sockolosky J, Trotta E, Parisi G, Picton L, Su L, Le A . Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018; 359(6379):1037-1042. PMC: 5947856. DOI: 10.1126/science.aar3246. View

15.

Drerup J, Liu Y, Padron A, Murthy K, Hurez V, Zhang B . Immunotherapy for ovarian cancer. Curr Treat Options Oncol. 2015; 16(1):317. PMC: 4355232. DOI: 10.1007/s11864-014-0317-1. View

16.

Sharma M, Khong H, Faak F, Bentebibel S, Janssen L, Chesson B . Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020; 11(1):661. PMC: 6994577. DOI: 10.1038/s41467-020-14471-1. View

17.

Krieg C, Letourneau S, Pantaleo G, Boyman O . Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010; 107(26):11906-11. PMC: 2900642. DOI: 10.1073/pnas.1002569107. View

18.

Raeber M, Rosalia R, Schmid D, Karakus U, Boyman O . Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity. Sci Transl Med. 2020; 12(561). DOI: 10.1126/scitranslmed.aba5464. View

19.

Cho H, Reyes-Vargas E, Delgado J, Celis E . A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 2012; 72(8):1986-95. PMC: 3328656. DOI: 10.1158/0008-5472.CAN-11-3246. View

20.

Hsu E, Cao X, Moon B, Bae J, Sun Z, Liu Z . A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021; 12(1):2768. PMC: 8119481. DOI: 10.1038/s41467-021-22980-w. View